SynthesisJournal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology2025
Deciphering NOTCH1 as a Biomarker in Adenoid Cystic Carcinoma: Insights From a Systematic Review With Meta-Analysis.
Synthesis in Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deciphering NOTCH1 as a Biomarker in Adenoid Cystic Carcinoma: Insights From a Systematic Review With Meta-Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2025Pooled it
- AKT, ATR, and Notch Inhibitors Radiosensitize a Preclinical Model of Adenoid Cystic Carcinoma.Head & neck · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMost studies suggest that NOTCH1 alterations are associated with prognosis in adenoid cystic carcinoma (ACC), but findings remain fragmented. We conducted an integrative analysis to evaluate the prognostic value of NOTCH1-related biomarkers in ACC.
methodsA comprehensive search was conducted across multiple databases. Inclusion criteria comprised studies examining NOTCH1-related features at ACC diagnosis and their relation with survival outcomes. Meta-analysis was performed on studies sharing similar methodology.
resultsTwelve studies met the eligibility criteria. NOTCH1 mutational status, Notch1 immunoexpression, and NICD1 immunoexpression were associated either with overall, disease-free or progression-free survival. Methodological disparities hindered integration of results. Meta-analyses of HRs were conducted with 2 studies for each index factor, revealing a 2.31-fold increased risk of death for primary ACC cases with NOTCH1 mutations, a 2.6-fold increased risk of death for those exhibiting positive NICD1 expression and a 1.91-fold heightened risk of disease recurrence for cases with high Notch1 expression.
conclusionThis comprehensive review underscores the prognostic relevance of NOTCH1 in ACC, indicating its potential as a valuable risk stratification tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.